Paul Robustelli

Nov 15, 2024 | biorxiv.org | Jiaqi Zhu |Paul Robustelli

AbstractIntrinsically disordered proteins are implicated in many human diseases. Small molecules that target the disordered androgen receptor transactivation domain have entered human trials for the treatment of castration-resistant prostate cancer. These molecules have been shown to react with cysteine residues of the androgen receptor transactivation domain and form covalent adducts under physiological conditions.